| 09:00–10:30 |
Parallel Workshops
An Apple a Day... Could It Be True? Epigenomics Shaping Personalized Medicine
Level 1
Yellow Hall 2
Epigenomics is not only challenging long-held notions about heredity but it is also providing a revolutionary roadmap for the development of new pharmacogenomic diagnostics and therapeutics. Researchers are using epigenomic approaches to gain a better understanding of a host of human ills, including cancer, neurological disorders, cardiovascular disease, and diabetes. During this workshop officials and scientists from cutting-edge biotech companies will discuss the range of tools and techniques they are employing to increase our knowledge of gene expression and pharmacogenomics. Their ultimate goal is to gain a deeper insight into the epigenetic mechanisms underlying individual drug response and to create novel tests and drugs based on these findings.
Moderator:
John Sterling – Editor in Chief, Genetic Engineering & Biotechnology News (GEN)
Panelists:
- Mohammad Azab – CMO, SuperGen
- Paul Denny-Gouldson – VP of Healthcare, IDBS
- Nicola Henneberg-Busse – VP, BD, Epigenomics AG
- David Simmons – CSO, Cellzome
Due Diligence: How To Ensure a Successful Process
Level 1
Blue Hall 1
M&A or partnering agreement, product or technology—a biotech company should be prepared to open its doors, books and personnel to a potential partner for full disclosure. Especially for large deals, due diligence is a complex commercial, legal and financial analysis that involves many within the biotech company and needs to be well orchestrated. Various companies have their own processes in place for how to conduct a thorough due diligence. This workshop will give guidance on what needs to be taken into consideration. How can a biotech company prepare for this process? Who needs to be involved? What is the expectation of timing for what needs to be accomplished? What does the pharma side expect to see and what do they not want to see? Panelists will draw from their due diligence experience and discuss what worked and what did not work so well.
Moderator:
Martina Molsbergen – CEO, C14 Consulting Group
Panelists:
- Jonathan Ellis – VP, Business Development, Biopharm R&D, GlaxoSmithKline
- Carl Jessop – Due Diligence Director, AstraZeneca
- Lali Reddy – Manager, Business Development, Genentech
- Morag Simpson – VP, Specialty Pharma New Product Assessment, Shire
- Gregory Wiederrecht – VP and Head, External Scientific Affairs, Merck & Co., Inc.
Oncology Drug Development Partnerships: Will Risk Sharing Models Work?
Level 1
Yellow Hall 3
In this capital-constrained environment, most oncology drug development companies will need clinical-stage partnerships to advance their programs through proof of concept into late stage development. To what extent can risk sharing partnerships with non-traditional partners offer alternatives to the back-ended, option deals with big pharma that leave little room for adaptive clinical strategies? This panel will examine the thought process around new partnering models in oncology and the pros and cons associated with different strategies.
Moderator:
Chris Hollowood – Partner, Apposite Capital
Panelists:
- Lukas Huber – CSO, Oncotyrol
- Phil L'Huillier – Director, Business Development, Cancer Research Technology
- Elisabeth Lindner – Senior Project Manager, Central European Cooperative Oncology Group (CECOG)
- Christian M. Pangratz – Executive Director, Business Development, NEKTAR
Understanding the Drivers for Strategic Decision Making
Level 1
Blue Hall 2
At every stage of its evolution, a development-stage biotech company must operate with a forward looking perspective. To advance assets, raise funds, select a great management team, and set strategic goals, the company must first evaluate where they want to go, and when and how they plan to get there. Should the company “go it alone,” bringing the asset to market singlehandedly, or should they license or co-develop with a partner, sell the asset, or determine an exit for the entire company? Understanding the key implications of these options and choosing the best path for each specific situation is critical to success. This panel will discuss not only the merits and “fit” of each approach, but how the decisions need to be reflected in the company’s development well before it becomes time for implementation.
Moderator:
Diane Romza-Kutz – Partner, Troutman Sanders
Panelists:
- Steven P. Damon – Senior VP, Business Development, Altea Therapeutics
- Steve Ellul – Director, Business Development, Eurand Pharmaceutical Technologies
- Leslie Molony – Senior Director, Business Development, Sanford-Burnham Medical Research Institute
- Michael A. Yeomans – President, Partners in Pharma
|
| 13:30–18:15 |
Parallel Panel Discussions
| Business Development |
| 13:30–14:30 |
What Makes a Great Biotech Company?
Level 1
Blue Hall 1
Over the past eight years John Carroll, the editor of FierceBiotech, has highlighted 120 biotech companies as among the best in the industry. He will lead a group of industry leaders, including executives from Fierce 15 companies, in a discussion of the key attributes that characterize the best in biotech. What is it that venture groups, big pharma partners and leading journalists look for when singling out top developers? And what can you learn from them?
Moderator:
John Carroll – Editor in Chief, FierceBiotech
Panelists:
- Katrine Bosley – CEO, Avila Therapeutics
- Lubor Gaal – Executive Director, Strategy, Alliances and Transactions, Bristol-Myers Squibb
- Simon Meier – Investment Director, Roche Venture Fund
- James J. O'Mara – VP, Business Development, Ironwood Pharmaceuticals
|
| 14:45–15:45 |
Deconstructing the Deal: A Close Look at Recent Dealmaking Activities
Level 1
Blue Hall 1
This session examines some of the significant deals of the last 12 months. The panel will discuss the transactions they have been involved in, and what these deals reveal about pharma’s priorities, strategy and the options available to drug development companies in need of a corporate partner.
Moderator:
Tony Gibney – Managing Director, Leerink Swann
Panelists:
- Bernard Davitian – VP, Deputy Corporate Licenses, Strategy and BD, sanofi-aventis
- Mercedes Diz – Associate Director, Licensing and Corporate Development, Almirall
- Philippe Lopes-Fernandes – VP, Head of Global Corporate BD, Merck Serono
- Jeremy P. Springhorn, PhD – VP, Corporate Strategy and Business Development, Alexion Pharmaceuticals, Inc.
- Clifford J. Stocks – Chief Business Officer, Calistoga Pharmaceuticals, Inc.
|
| 16:00–17:00 |
Pharma Out-licensing: What Do They Have and Where Do They Have It?
Level 1
Blue Hall 1
Not many big pharma players are very proactive in out-licensing, however some of them seem to have revived outbound partnering activities recently. There are more and more examples of successful deals and out-licensed compounds reaching the market. Shelved compounds from big pharma can still be of high interest to small companies and specialty pharma and investors would love to fund more out-licensing deals, but the originators often want to keep their stake in the asset. It takes creative deal structuring to allow both partners to identify sufficient value in a deal and to avoid regrets later.
Moderator:
Ben Bonifant – Senior VP and Practice Area Leader, Campbell Alliance
Panelists:
- Glenn Batchelder – President and CEO, Civitas Therapeutics
- Ian Kirk – Director, Corporate Business Development, AstraZeneca
- Markus Werner – Director Corporate Licensing, Business Development, Nycomed
- Robert Wills – VP, Alliance Management, Pharmaceuticals Group, Johnson & Johnson
|
| 17:15–18:15 |
Breaking Ground in Personalized Medicine: What Do the Recent Deals Mean for Drug Development?
Level 1
Blue Hall 1
"Personalized Medicine" seems to be the buzzword for the life science industry. Though for a while it was mainly seen as a threat to their blockbusters, pharma companies are now realizing that the shift towards personalized medicine will happen, and that they must adapt accordingly. Recent deals reflect the rising emphasis of companion diagnostics and biomarkers in drug development, but many questions still go unanswered. Who will be setting benchmarks and dictating the deal terms around personalized medicine, pharma or diagnostics? Which other healthcare players will be involved? Are there viable business models for companion diagnostics today? In lieu of a reliable crystal ball, this panel will take a close look at recent deals around personalized medicine and discuss how these deals are leading the way into a new era in life sciences.
Moderator:
Alain Huriez, MD – CEO, TcLand Expression, Chairman EPEMED
Panelists:
- Harry Glorikian – Managing Partner, Scientia Advisors
- Gabriela Lavezzari – Senior Manager, Extramural R&D, Medco Research Institute
- Richard Watts – Director Pharma Business Development, QIAGEN
- Matthias Will – Head Marketing & Market Access, Molecular Diagnostics, Novartis Pharma
|
| In the Spotlight |
| 13:30–14:30 |
The Road Less Traveled: Understanding Unconventional Financing and Partnering Options
Level 1
Blue Hall 2
Many experts believe the era of the conventional venture-backed financing model to fund drug development has passed. If this is true, what new models or funding options are taking its place? This panel will discuss some of the alternative paths to funding drug discovery and development, including new partnering structures, in a challenging economic environment.
Moderator:
Morrie Ruffin – Managing Partner, Adjuvant Global Advisors
Panelists:
- Kenneth A. Bertram, MD, PhD – Principal Assistant for Acquisition, U.S. Army Medical Research and Materiel Command
- Karin Hehenberger – Senior VP, Strategic Alliances, Juvenile Diabetes Research Foundation (JDRF)
- Jürgen Langhärig – VP, Business Development, Bavarian Nordic
- Eric I. Richman – President and CEO, PharmAthene
|
| 14:45–15:45 |
Financing Innovation: A Conversation With US and European VCs Who Still Invest Early
Level 1
Blue Hall 2
Investing in life science companies has always presented special challenges to venture capitalists. And the math is only getting worse, as timelines, costs and regulatory hurdles increase while exit opportunities have nearly vanished. How are current VCs, especially those who became life science investors because they love the science, coping with these new realities? Is there a recipe for successful investing in early stage science? Will recent initiatives from both government and industry designed to husband early-stage science out of academic institutions help or hurt the venture industry?
Moderator:
Michael Gilman – CEO, Stromedix
Panelists:
- Kevin Johnson – Partner, Index Ventures
- Elaine V. Jones – Executive Director, Venture Capital, Pfizer, Inc.
- Nilesh Kumar, PhD – Associate Director, Merck Serono Ventures
- Manuel Lopez-Figueroa – VP, Bay City Capital
|
| 16:00–17:00 |
Successful Approaches for Biotech Companies Entering China
Level 1
Blue Hall 2
Our panel of executives and professionals will provide real world examples of how companies take advantage of opportunities in China. They will draw from their experience in areas such as co-development, joint ventures, financing and services.
Moderator:
Ian Wisenberg – Managing Director, ChinaBio® Capital Partners
Panelists:
- Paul Grayson – Managing Director, Access BioVentures
- Alicia Hong – Head of China Practice, WilmerHale
- John Oyler – CEO, BeiGene
- Peng Wang – CSO, Simcere
|
| 17:15–18:15 |
Deal or No Deal? The Changing and Increasing Importance of BD in Pharma and Biotech
Level 1
Blue Hall 2
Seasoned BD executives share their partnering war stories and resulting best practices, discussing:
- What is the range of activities that BD undertakes to get a deal done? Where does the job end: after the scouting, after due diligence, after the deal, or does the BD person manage the entire project?
- When a deal fell through, who walked away and why?
- Is the process from technology sourcing to deal efficient? Could it be improved?
- How is the face of BD changing? Will the absolute requirement for more deals with biotech, and the shrinking size of pharma R&D groups, put pressure on the relationship between biotech and pharma?
Moderator:
Mike Ward – Editor in Chief, Scrip Group
Panelists:
- Gil Ben-Menachem – Director, Business Development, Global Branded Products, Teva Pharmaceutical Industries
- Neill Moray Mackenzie – CEO, CMP Therapeutics
- Ian Moules – Senior Director, Business Development, Takeda Pharmaceuticals Europe
- Yetunde Taiwo – Senior Director, Global External Research & Development, Lilly
|
|
Therapeutic Insight by Defined Health
|
|
Defined Health’s Therapeutic Insight, now in its eleventh year, is a forum for senior industry executives to gain an enriched understanding of transformational challenges emerging across the industry and within the scientific, clinical and commercial spectra of selected disease and technological areas. Therapeutic Insight sessions connect the "big picture" with the real world of drug development and commercialization issues. Uniting "30,000 foot" viewpoints with tangible analysis of pipeline products, standards of care and epidemiology, the sessions also take a close look at development and regulatory issues as well as market dynamics.
|
| 13:30–14:30 |
Proof of Relevance: The New Standard for Partnering
Level 1
Yellow Hall 3
Presenter:
Ed Saltzman – President, Defined Health
|
| 14:45–15:45 |
Therapeutic Insight: Oncology
Level 1
Yellow Hall 3
Moderator:
Jeffrey M. Bockman – VP, Defined Health
Panelists:
- Louis J. DeGennaro – Executive VP and Chief Mission Officer, The Leukemia & Lymphoma Society
- George S. Golumbeski – Senior VP, Business Development, Celgene Corporation
- Fran Heller – Executive VP, Business Development, Exelixis
- Dr Peter Sandor – Head of Strategy and Portfolio Development, BU Specialized Medicine, Bayer HealthCare
|
| 16:00–17:00 |
Therapeutic Insight: Orphan Diseases
Level 1
Yellow Hall 3
Moderator:
Aileen Nicoletti – VP, Defined Health
Panelists:
- Gary Clements – Senior Director, Business Development, Shire
- Leslie Coney – Director, Worldwide R&D Business Development, Pfizer, Inc.
- Teresa Moss – Director, National Specialised Commissioning, National Health Service (NHS), UK
|
| 17:15–18:15 |
Therapeutic Insight: Respiratory Diseases
Level 1
Yellow Hall 3
Moderator:
Timothy Joslin – Managing Director, Europe, Defined Health
Panelists:
- Tim Higenbottam – Director of Corporate Clinical Development, Chiesi Farmaceutici
- Stéphane Kirkesseli – VP, Investigational Medicine, Immuno-inflammation Unit, sanofi-aventis
- Dr Mark V. Rogers – Business Development Director, Respiratory, AstraZeneca
|
| International Seminars and Presentations |
| 13:30–14:30 |
The Netherlands
Level 1
Yellow Hall 2
Competitive Cooperation Through Strong Alliances and Partnerships
The Dutch are famous for their ability to build broad coalitions and form strong strategic alliances whether to keep out high seas or to breed a competitive life science sector. The Netherlands is the most concentrated region in the world in terms of working to create economic and social value in life sciences and health:
- with the highest concentration of knowledge institutes, public/private consortia, SMEs
- with organized and documented patient groups in a small geographic region
- with a strong connection between the academic organizations
- with a leading scientific position
- with an outstanding infrastructure from education to biobanks
Collaboration is in our genes. This is also illustrated by the fact that five of the top ten European biotech-pharma partnerships involve Dutch SMEs. This session will elaborate on the opportunities the Netherlands can offer. Speakers from Dutch innovative SMEs will present their companies and products and the possibilities to cooperate with you.
Speakers:
- Roland Lageveen – CEO, IQ Corporation
- Ada Kruisbeek – CEO, DC Prime
- Herman Steen – CEO, BiOrion Technologies
- Bastiaan de Leeuw – CEO, NovioGendix
- Maurits Peverelli – Director Sales & Marketing, Polyganics Holding
- Jos Raats – President and CEO, ModiQuest Research
- Ad van Gorp – CEO, Lead Pharma Holding
- Andy Lewin – Senior Manager Business Development, Octoplus
- Remko Clasen – Business Development Manager, BAC
- Ivor Hidding – Technical Account Manager, Winclove BIO Industries
|
| 14:45–15:45 |
Canada
Level 1
Yellow Hall 2
Canada's Advantages in Life Sciences
Canada Ahead of the Curve
Canada's position as a biotechnology leader—one of the top five countries in the world—is a reflection of the country's world-class credentials. The biotech industry also benefits from powerful partnerships that strengthen government research dollars through collaboration with universities and industry, as well as progressive financing and venture capital programs for Canadian biotech enterprises.
Some key facts:
- Canada’s bio-based economy totals CAD 78.3 billion in sales, and leads the G7 in the growth of health research patents.
- Canada’s life sciences industry is supported by a top-notch research community of over 100 institutes, 670 biotech companies and over 28,000 employees.
- Canada’s domestic pharmaceutical industry is a CAD 20 billion market, the world’s ninth-largest.
- Among our peer G7 nations, Canada’s biopharmaceuticals industry is the fastest-growing.
- Canadian biotech and pharmaceutical firms have over 300 products under development or on the market, and annual spending on biopharmaceutical R&D in Canada is CAD 1.3 billion.
- Montréal, Toronto and Vancouver are important North American clusters for biotech activity, and are consistently ranked in the Top 10 cities in North America for life science patents.
- Key areas of Canadian biopharma expertise include vaccine R&D and production, central nervous system (CNS), oncology, contract research and clinical trials.
Speakers:
- Peter Brenders – President, BIOTECanada
- Francis Beaulieu – Director Business Development and Strategic Partnerships, Montréal InVivo
|
| 16:00–17:00 |
Italy
Level 1
Yellow Hall 2
An Overview of the Leading Actors in Italian Biotech Growth
Vigorous growth and an excellent capacity for innovation are the principal characteristics of the Italian biotech sector. An overview of the leading actors in Italian biotech growth will be offered. AIFA, the Italian competent authority for drugs, will comment on the regulatory situation in the country, whereas ICE, the Italian Institute for Foreign Trade, and Invitalia, the Italian government agency for inward investment promotion and enterprise development, will illustrate the business opportunities. The panel will emphasize the abilities of the Italian biotech sector to optimize research investments, generating a growing value production through the years despite difficulties in raising funds worsened by the economic crisis.
16:00
Welcome and Introduction
- Alessandro Sidoli – President, Assobiotec
16:05
The Italian Biotech Sector
- Alessandro Sidoli – President, Assobiotec
16:15
The Italian Pharmaceutical Sector
- Sergio Dompé – President, Farmindustria
16:25
The Regulatory Advantages
- Carlo Tomino – Clinical Research Director, AIFA
16:35
The ICE's Network
- Ambassador Umberto Vattani – President, Italian Institute for Foreign Trade (ICE)
16:45
Business Support in Italy
- Giuseppe Arcucci – Director, Inward investment Unit, Invitalia
16:55
Q&A and Conclusion
|
| 17:15–18:15 |
Belgium–Wallonia
Level 1
Yellow Hall 2
Cell Therapy as a Case Study
In 2005, the regional government of Wallonia (Belgium) launched a strategic plan to boost innovation by capitalizing on the area’s strengths. Under this plan, which mobilized EUR 1.5 billion over four years (2005–2009), EUR 300 million was allocated in 2006 to the creation of five competitiveness clusters. One of these clusters, BioWin, is dedicated to the health sector. This plan is now further developing (2009-2014) with the ambition to amplify the initial successes of the ‘poles’ and to extend the capabilities of this regional policy.
This very proactive policy intends to accelerate innovation by encouraging universities and industry (mostly SMEs) to work together. In these partnerships, industry takes the lead to ensure that innovative products/services are created for new markets. Wallonia has the following major strengths in the field of biotechnology linked to health: excellence in academic and industrial research; a unique academic and industrial network; a high concentration of university hospitals (Belgium has the world’s highest proportion of clinical trials per capita); and a broad offering of science parks with incubation and innovation centers at low land prices.
During this session, we would like to share with you the promising story of a European region that invests in a technology, cell therapy, that is key for the future of medicine as well as for the economic development of the region.
The speakers will also show you how you can integrate your business project in cell therapy in Wallonia.
Speakers:
New Avenues for Fruitful Biomedical Cooperation in the Heart of Europe
- Dr Philippe Janssens de Varebeke – Life Sciences Expert, Awex
BioWin: Where Science Meets Business
- Frédéric Druck (Moderator) – Communication and International Relations Director, BioWin
MaSTherCell: Manufacturing Synergies for Therapeutic Cells
- Didier Argentin – Chief Business Officer, MaSTherCell
|
|
13:30–18:30
One-to-one Meetings ►
|
Evening Networking
Reception
Evening Networking Reception
Life Sciences Health
